Clinical and Radiographic Improvement of Neurodegenerative Langerhans Cell Histiocytosis (ND-LCH) Following Dabrafenib (P3.266)

Conclusion: These preliminary results suggest that dabrafenib may be a promising new therapy for ND-LCH, with rapid improvement seen following years of neurologic decline. Further investigation of this therapy in ND-LCH is warranted.Disclosure: Dr. Yeh has nothing to disclose. Dr. Leary has nothing to disclose. Dr. Longoni has nothing to disclose. Dr. Abla has nothing to disclose. Dr. Shelia has nothing to disclose. Dr. Whitlock has nothing to disclose.

Source: Neurology - April 3, 2016 Category: Neurology Authors: Yeh, E. A., Leary, S., Longoni, G., Abla, O., Shelia, W., Whitlock, J. Tags: Child Neurology and Developmental Neurology: Other Source Type: research